AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33507604
Drug: Vincristine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine and topotecan (VT) neoadjuvant intravenous chemotherapy
Trial: 33507803
Drug: Autologous T-cell
RxNorm normalized name: an autologous T-cell immunotherapy (ET140203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous T-cell product targeting multiple tumor-associated antigens (TAAs) including PRAME, SSX2, MAGEA4, SURVIVIN, and NY-ESO-1, administered at a fixed dose of 0.5 × 10^6 T cells, with a maximum tested dose of two infusions of 2 × 10^6 T cells
Trial: 33507822
Drug: Mirdametinib (PD-0325901)
RxNorm normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirdametinib (PD-0325901) at 2 mg/m, administered by mouth twice a day
Trial: 33508475
Drug: Modified Duke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Duke criteria, heart murmur, and intensive care therapy
Trial: 33509135
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT), 10 sessions as part of normal clinical management.
Trial: 33512057
Drug: 7-day ECG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day ECG patch monitor
Trial: 33512323
Drug: Therapist-guided online
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided online therapy (1 session per week for 6 weeks, utilizing cognitive behavioral therapy and acceptance and commitment therapy)
Trial: 33512323
Drug: Self-help internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help internet-based therapy (automatic weekly newsletter with self-help information and tips)
Trial: 33512323
Drug: Therapist-guided online
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided online therapy
Trial: 33512323
Drug: Self-help internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help internet-based therapy
Trial: 33512414
Drug: CAR22 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAR22 therapy (1 × 10^6 CAR+ T cells per kilogram targeting CD22)
Trial: 33512414
Drug: CAR22 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAR22 therapy
Trial: 33512441
Drug: ≥1 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥1 injection per week (18.1% of patients, n=37)
Trial: 33512441
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment (16.6% of patients, n=34)
Trial: 33512452
Drug: VLS-101 (antibody-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLS-101 (antibody-drug conjugate targeting ROR1)
Trial: 33512666
Drug: Risankizumab 90
RxNorm normalized name: Risankizumab 90.361 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 90 or 180 mg every 12 weeks for at least 48 weeks
Trial: 33512794
Drug: MOWOOT device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOWOOT device (intermittent colonic exo-peristalsis) used daily for 20 minutes over 4 weeks
Trial: 33513372
Drug: MATRix-RICE (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MATRix-RICE (rituximab 375 mg/m2) plus autologous HSCT
Trial: 34794172
Drug: Hypomethylating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypomethylating agents
Trial: 33513645
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone supplementation
Trial: 33514524
Drug: LY3321367 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3321367 with LY300054 (anti-PD-L1 antibody)
Trial: 33516248
Drug: Cluster analysis
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster analysis of biological markers
Trial: 36395989
Drug: Vortioxetine 10-20
RxNorm normalized name: vortioxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10-20 mg/day for 8 weeks
Trial: 33516721
Drug: Idelalisib interruption
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib interruption after ≥ 6 months of treatment
Trial: 33516721
Drug: Idelalisib interruption
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib interruption with dose reduction
Trial: 33516721
Drug: Time off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time off therapy of ≥ 8%
Trial: 33517043
Drug: Radiotherapy (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (conventional fractionation and hypofractionation); dose range: 43.4 to 71.0 Gy (median dose: 48.6 Gy); boost radiation therapy administered to 49 patients.
Trial: 33517477
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) discontinuation
Trial: 33517701
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment on hospital admission (21.7%)
Trial: 33517701
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of prior statin treatment
Trial: 33518355
Drug: Ranolazine 375-750
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine 375-750 mg (single-dose and multiple-dose)
Trial: 33519339
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (CP) transfusion (300 ml, 200-400 ml/treatment dose) at least once, up to 5 sessions, along with best standard of care.
Trial: 33520317
Drug: Prolonged-release pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prolonged-release pirfenidone (PR-PFD) 1,200 mg/day
Trial: 33520317
Drug: Prolonged-release pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prolonged-release pirfenidone (PR-PFD) 600 mg/day
Trial: 33521534
Drug: Medical prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical prescriptions for fresh vegetables (21 servings/week for 10 weeks)
Trial: 33522900
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of YKL-40 and MIP-1α in saliva
Trial: 33523334
Drug: BI 836826
RxNorm normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 836826 in combination with gemcitabine and oxaliplatin
Trial: 33524308
Drug: Uterine-sparing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterine-sparing treatment
Trial: 33524399
Drug: Leptin and
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin and gene signature for lymphocyte activation and dysregulated lipid metabolism
Trial: 33524601
Drug: Sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200 mg, day 1) and Anlotinib (12 mg, day 1-14) every 3 weeks
Trial: 33526918
Drug: Prior lines
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior lines of systemic immunosuppressive therapy for cGVHD
Trial: 33527351
Drug: Bayesian dose
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayesian dose regimen assessment method (DRtox)
Trial: 33527447
Drug: Palatal (P)
RxNorm normalized name: malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palatal (P) and Buccal (G) tissues
Trial: 33527447
Drug: G and
RxNorm normalized name: Calcium Mag And Zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G and P tissues
Trial: 33528118
Drug: Recombinant subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant subunit herpes zoster vaccine (RZV); 2 doses given 2-6 months apart.
Trial: 33528286
Drug: Single-agent selinexor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent selinexor
Trial: 33529058
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously once every 3 weeks for ≤ 24 months
Trial: 33529989
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg intravenously once every 3 weeks, 2 cycles prior to surgery)
Trial: 33530933
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of biomarkers with clinical risk factors
Trial: 33531464
Drug: Estradiol challenge
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol challenge test (specific dosage and duration not provided)
Trial: 33533507
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg QD on Days 1-5
Trial: 33533507
Drug: GSK3640254 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 200 mg QD on Days 1-7
Trial: 33533507
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg plus GSK3640254 200 mg QD on Days 1-7
Trial: 33533986
Drug: Individualized management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized management of breakthrough cancer pain (BTcP) therapy
Trial: 33534266
Drug: Specific COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific COVID-19 pharmacotherapy
Trial: 33535013
Drug: Insulin suspension
RxNorm normalized name: Insulin Suspension Isophane (NPH) (Recombinant)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin suspension during overnight basal up-titration
Trial: 33535600
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibition as primary adjuvant therapy
Trial: 33536021
Drug: Intravenous selexipag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous selexipag
Trial: 33536130
Drug: Amisulpride treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride treatment for 4 weeks
Trial: 33536430
Drug: MR-guided focused
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-guided focused ultrasound (MRgFUS) with intravenous microbubble administration
Trial: 33536791
Drug: Multi-professional medication
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-professional medication reviews (MRs)
Trial: 33536998
Drug: Bicycle simulator
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicycle simulator training, details on dosage and duration not available
Trial: 33537232
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for four cycles.
Trial: 33537232
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with FLOT regimen for four cycles.
Trial: 33537232
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival (OS) and relapse-free survival (RFS) outcomes after treatment.
Trial: 33537564
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose subcutaneous sterile water injection
Trial: 33537564
Drug: Subcutaneous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous saline injection
Trial: 33538517
Drug: Immediate-release carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release carbidopa/levodopa (IR)
Trial: 33538517
Drug: Controlled-release carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release carbidopa/levodopa (CR)
Trial: 33538517
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in levodopa equivalent daily dose
Trial: 33538517
Drug: Schwab and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwab and England Activities of Daily Living Scale
Trial: 33538699
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health and self-management app (8-week program including Lung Attack Action Plan, education, medication overview, video consultation, and questionnaires)
Trial: 33538761
Drug: Povidone Iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone Iodine Mouthwash, Gargle, and Nasal Spray
Trial: 33539144
Drug: Unified Protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Trial: 33540481
Drug: Latency reversal
RxNorm normalized name: edrophonium chloride Injectable Solution [Reversol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latency reversal agents
Trial: 33540485
Drug: DalcA (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DalcA (subcutaneous 150 IU/kg daily for 6 days)
Trial: 33540485
Drug: DalcA (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DalcA (intravenous 75 IU/kg)
Trial: 33540485
Drug: DalcA (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DalcA (subcutaneous 75 IU/kg)
Trial: 33540485
Drug: DalcA (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DalcA (subcutaneous 150 IU/kg)
Trial: 33540485
Drug: BeneFIX (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BeneFIX (intravenous 75 IU/kg)
Trial: 33541235
Drug: Home nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home nebulizer inhaled corticosteroid (ICS) therapy
Trial: 36219388
Drug: Triple inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple inhaled therapy
Trial: 33541356
Drug: Bronchodilators for
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators for monotherapy
Trial: 33541436
Drug: Truncal ablation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Truncal ablation, simultaneous iliac interrogation with intravascular ultrasound and stenting of significant (> 50%) iliac vein lesions plus compression therapy
Trial: 33541436
Drug: Truncal ablation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Truncal ablation and compression therapy
Trial: 33542056
Drug: 40 mg·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg·kg of rifampicin
Trial: 33542056
Drug: 50 mg·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg·kg of rifampicin
Trial: 33542131
Drug: Responder-derived fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responder-derived fecal microbiota transplantation (FMT) together with anti-PD-1 therapy
Trial: 33542624
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI (budesonide/glycopyrrolate/formoterol fumarate) 320/18/9.6 µg
Trial: 33542624
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI (glycopyrrolate/formoterol fumarate) 18/9.6 µg
Trial: 33543056
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment after 14 weeks)
Trial: 33544318
Drug: Vedolizumab 300-mg
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300-mg maintenance therapy every 8, 6, or 4 weeks
Trial: 33544318
Drug: Vedolizumab 300-mg
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300-mg maintenance therapy every 8 weeks
Trial: 33544318
Drug: Vedolizumab 300-mg
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300-mg maintenance therapy
Trial: 33545083
Drug: Rescue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy (including primary induction) or colectomy during the COVID-19 pandemic period
Trial: 33545083
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to rescue therapy during the COVID-19 pandemic period
Trial: 33545083
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of rescue and primary induction therapies with biologicals, ciclosporin, or tofacitinib during the COVID-19 pandemic period
Trial: 33545083
Drug: Ambulatory (outpatient)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory (outpatient) intravenous steroids during the COVID-19 pandemic period
Trial: 33545083
Drug: Incidence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incidence of SARS-CoV-2 during hospital treatment
Trial: 33545389
Drug: ALK inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALK inhibitors (ALKi)
Trial: 33545440
Drug: Therapeutic rest
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic rest using intramuscular morphine sulfate and promethazine
Trial: 33546641
Drug: Brief individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief individual oral and visual information on vitamin D given by doctors at baseline and after four and ten months
Trial: 33546731
Drug: Frailty score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frailty score pre-chemotherapy (T1) vs post-chemotherapy (T2)
Trial: 33547528
Drug: P-PENK >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-PENK > 84.8 pmol/mL at baseline
Trial: 33547528
Drug: P-NGAL >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-NGAL > 104 ng/mL at baseline
Trial: 33547559
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus doses of morphine via patient-controlled analgesia
Trial: 33547694
Drug: Equine-assisted therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equine-assisted therapy (EAT)
Trial: 33548397
Drug: Brodalumab (IL-17RA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab (IL-17RA antagonist)
Trial: 33548468
Drug: Reslizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reslizumab (3 mg/kg)
Trial: 33548471
Drug: Inhaled triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled triple therapy
Trial: 33549128
Drug: ERITA (Emotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERITA (Emotion Regulation Individual Therapy for Adolescents) as an add-on to treatment as usual
Trial: 33549447
Drug: Urinary potassium
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary potassium excretion in black individuals
Trial: 33550173
Drug: Ticagrelor administration
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor administration
Trial: 33550824
Drug: Furosemide, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide, dosage and duration not specified
Trial: 33550846
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid testing (OFT) - supervised testing
Trial: 33550846
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid testing (OFT) - unsupervised testing
Trial: 38877777
Drug: Intravascular lithotripsy
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular lithotripsy (IVL) treatment
Trial: 34941429
Drug: Transcranial Photobiomodulation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Photobiomodulation, details on dosage and duration not available
Trial: 33551992
Drug: Lutetium 177-DOTATATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutetium 177-DOTATATE therapy
Trial: 33553233
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of cinnamon added to oatmeal prepared with milk
Trial: 33554038
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg intravenously every 3 weeks)
Trial: 33554514
Drug: MR-proADM threshold
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-proADM threshold of 1.75 nmol/L
Trial: 33555033
Drug: Ribociclib 400
RxNorm normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 400 mg single oral dose